Physician profile
Joan Eldridge
NPI 1689220154
$4,363.95
in general payments reported to CMS, 2019-2025
29 companies · $666 in 2025
The $666 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $799 · 2022: $887 · 2023: $1,041 · 2024: $971 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.75 | 2021-2025 | |
| Novo Nordisk INC | $690.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.23 | 2022-2025 | Relistor, Xifaxan |
| Abbott Laboratories | $202.84 | 2021-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $202.13 | 2024-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.08 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $189.44 | 2021-2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $167.96 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $158.01 | 2022-2025 | |
| Indivior INC. | $109.91 | 2021-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $101.77 | 2021-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $90.93 | 2021 | |
| Merck Sharp & Dohme LLC | $87.00 | 2021-2023 | Verquvo, Belsomra |
| Kowa Pharmaceuticals America, INC. | $68.96 | 2022-2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $68.27 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.82 | 2023-2025 | Repatha, Otezla, Repatha |
| Alkermes, INC. | $61.44 | 2025 | Vivitrol |
| Glaxosmithkline, LLC. | $51.28 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $49.21 | 2025 | The Cologuard Plus Collection Kit |
| Halozyme INC | $44.54 | 2023 | |
| Idorsia Pharmaceuticals US INC | $41.58 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $38.45 | 2023-2024 | Sunosi |
| Vertex Pharmaceuticals Incorporated | $30.79 | 2025 | |
| Dexcom, INC. | $26.93 | 2025 | Dexcom G6 Transmitter |
| Adlon Therapeutics L.P. | $25.26 | 2021 | |
| Braeburn INC. | $22.74 | 2025 | Brixadi |
| Hologic Sales and Service, LLC | $16.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2021 | |
| Lundbeck LLC | $13.63 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.